CD8A and neoplasm: In CT26 tumor-bearing mice, PD-L1 mAb treatment significantly increased the infiltration of killer CD8+ T (GZMB) cells compared to IgG2a (Supplementary Fig. S12B, C) and markedly reduced tumor burden (Supplementary Fig. S12D, E).